Charles Bennett, MD, PhD, Discusses the FDA’s Biosimilar Approval Timeline
January 13th 2021Charles Bennett, MD, PhD, a hematologist and oncologist and professor in the Clinical Pharmacy and Outcomes Sciences Department of the College of Pharmacy at the University of South Carolina, discussed the FDA’s pace of biosimilar approvals and the findings from his recent study.
Part 2: Ivo Abraham, PhD, RN, Discusses the Pandemic’s Effect on Pegfilgrastim Biosimilar Use
January 5th 2021Ivo Abraham, PhD, RN, a professor with the University of Arizona Health Sciences in the Department of Pharmacy Practice and a health care consultant and co-founder of Matrix45, discussed how the pandemic is likely to impact the use of pegfilgrastim biosimilars.
Part 1: Ivo Abraham Talks About Biosimilar Pegfilgrastim Savings Amid COVID-19
December 21st 2020Ivo Abraham, PhD, RN, a professor in the Department of Pharmacy Practice at University of Arizona Health Sciences, and a health care consultant with Matrix45, discusses recent studies that demonstrated savings for pegfilgrastim vs the on-body injector.
Robert Rifkin, MD, Discusses Overcoming Lingering Biosimilar Education Gaps
December 5th 2020Robert Rifkin, MD, FACP, oncologist and hematologist with Rocky Mountain Cancer Centers and medical director of Biosimilars for McKesson, discusses how his practice is working to correct biosimilar education gaps among physicians and the consequences if those gaps are not addressed.
Part 2: Jorge Garcia on Giving Pharmacists Latitude to Switch to Biosimilars
November 25th 2020Jorge Garcia, PharmD, MS, MHA, MBA, assistant vice president of the System Oncology Pharmacy Service Line at Baptist Health South Florida, discussed how Baptist Health increases biosimilar use and how innovator companies fight to avoid biosimilar competition.
Jorge Garcia Talks About COVID-19’s Effect on Pegfilgrastim Biosimilars
November 18th 2020Jorge Garcia, MS, assistant vice president of the System Oncology Pharmacy Service Line at Baptist Health South Florida, discussed how the pandemic has interrupted oncology care for patients and affected the utilization of pegfilgrastim biosimilars.
Part 2: Nabeel Khan, MD, Discusses the Significance of a VA Study on Biosimilar Switching
November 7th 2020Nabeel Khan, MD, an associate professor of clinical medicine with the University of Pennsylvania, explains how a recent infliximab switching study builds support for use of biosimilars and early treatment with these agents.
Part 1: Nabeel Khan, MD, Discusses an Infliximab Double-Switching Study
November 4th 2020Nabeel Khan, MD, an associate professor of clinical medicine with the University of Pennsylvania, discussed a study in which patients were switched from reference and biosimilar forms of infliximab to another biosimilar infliximab, Renflexis.
Bhuvana Sagar, MD, Discusses Maintaining Cost Efficiency While Using Biosimilars
November 1st 2020Bhuvana Sagar, MD, the national medical executive at Cigna Health Care, discusses the importance of maintaining cost efficiency when juggling multiple biosimilars for 1 originator in the practice setting.
Sandoz’ Edward Li on Using Filgrastim to Ease the Risk of Febrile Neutropenia
October 20th 2020Edward Li, PharmD, director of Health Economics and Outcomes Research for Sandoz, discussed how biosimilar filgrastim (Zarxio) used as primary prophylaxis saves money and helps reduce the risk of febrile neutropenia in patients with cancer.
Thomas Wakim On Neuclone’s Early Dive Into Developing PD-1 Inhibitor Biosimilars
October 15th 2020Thomas Wakim, strategic analyst for Neuclone, discussed the company’s decision to break into the world of PD-1 inhibitors, its partnership with the Serum Institute in India, and Neuclone’s biosimilar pipeline.
Part 2: Sean McGowan on Ensuring a Future Competitive Biosimilar Market
October 1st 2020Sean McGowan, senior director of Biosimilars at AmerisourceBergen, discusses the physician and practice issues with having multiple biosimilars for the same molecule on the market and what is needed to ensure more biosimilar competition in the future.
Part 1: Sean McGowan on the Challenges of Bringing a Biosimilar to Market
September 29th 2020Sean McGowan, senior director of Biosimilars at AmerisourceBergen, discussed the challenges of bringing a new biosimilar to market both generally and during the time of the coronavirus disease 2019 (COVID-19) pandemic.
Hillel Cohen, PhD, on How to Avoid Confusion in Biosimilar Promotions
September 22nd 2020Hillel Cohen, PhD, Education Committee co-chair for the Biosimilars Forum and executive director of Scientific Affairs for Sandoz, discussed whether disclosure statements are needed for biosimilar products and what they should contain, according to the biosimilar industry perspective.
Part 2: Wayne Winegarden, PhD, on What Canada Can Teach the United States About Biosimilars
September 17th 2020Wayne Winegarden, PhD, senior fellow in business and economics at the Pacific Research Institute (PRI) and director of PRI’s Center for Medical Economics and Innovation, discussed why importing drugs may not lower costs and what we can learn from Canada’s biosimilar programs.
Part 1: Wayne Winegarden, PhD, on How Employers Can Better Manage Their Formularies
September 15th 2020Wayne Winegarden, PhD, senior fellow in business and economics at the Pacific Research Institute (PRI) and director of PRI’s Center for Medical Economics and Innovation, discussed where the biosimilar market is heading and how employers can incentivize biosimilar utilization.
Part 2: Brian Gifford on How Treatment Adherence Can Help Employers Save
September 10th 2020Brian Gifford, research director of the Integrated Benefits Institute (IBI), discussed how employers can improve treatment adherence for their employees with rheumatic conditions in order to keep them productive and on the job.
Part 1: Brian Gifford on the Hidden Costs of Rheumatoid Arthritis
September 8th 2020Brian Gifford, research director of the Integrated Benefits Institute (IBI), discussed employer challenges with managing expenses associated with rheumatoid arthritis and how skillful management of rheumatoid arthritis can keep employees on the job and reduce expense.
Part 2: Surya Singh, MD, on Whether Biosimilars Will Lower Drug Costs
September 3rd 2020Surya Singh, MD, president and owner of Singh Healthcare Advisors LLC in Lexington, Massachusetts, discussed the future for the US adalimumab market and whether biosimilars can deliver on the promise of lower cost health care.